Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].

Authors/Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG).

Atherosclerosis. 2019 Dec 4;292:160-162. doi: 10.1016/j.atherosclerosis.2019.11.020. [Epub ahead of print] No abstract available.

PMID:
31811963
2.

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies.

Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. No abstract available. Erratum in: Atherosclerosis. 2019 Dec 4;292:160-162.

PMID:
31591002
3.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group .

Eur Heart J. 2019 Aug 31. pii: ehz455. doi: 10.1093/eurheartj/ehz455. [Epub ahead of print] No abstract available.

PMID:
31504418
4.

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.

Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators.

Lancet. 2019 Sep 28;394(10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1.

5.

Ticagrelor in Patients with Stable Coronary Disease and Diabetes.

Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators.

N Engl J Med. 2019 Oct 3;381(14):1309-1320. doi: 10.1056/NEJMoa1908077. Epub 2019 Sep 1.

PMID:
31475798
6.

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion.

Banach M, Bruckert E, Descamps OS, Ellegård L, Ezhov M, Föger B, Fras Z, Kovanen PT, Latkovskis G, März W, Panagiotakos DB, Paragh G, Pella D, Pirillo A, Poli A, Reiner Ž, Silbernagel G, Viigimaa M, Vrablík M, Catapano AL.

Atheroscler Suppl. 2019 Aug 17. pii: S1567-5688(19)30046-7. doi: 10.1016/j.atherosclerosissup.2019.08.023. [Epub ahead of print] No abstract available.

PMID:
31451336
7.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

PMID:
31272931
8.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

9.

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, Cicero AFG; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP).

Pharmacol Res. 2019 May;143:1-16. doi: 10.1016/j.phrs.2019.02.028. Epub 2019 Mar 4. Review.

PMID:
30844537
10.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
11.

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators.

N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.

12.

Serum Uric Acid in Roma and Non-Roma-Its Correlation with Metabolic Syndrome and Other Variables.

Petrikova J, Janicko M, Fedacko J, Drazilova S, Madarasova Geckova A, Marekova M, Pella D, Jarcuska P.

Int J Environ Res Public Health. 2018 Jul 4;15(7). pii: E1412. doi: 10.3390/ijerph15071412.

13.

The Role of Nutraceuticals in Statin Intolerant Patients.

Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP).

J Am Coll Cardiol. 2018 Jul 3;72(1):96-118. doi: 10.1016/j.jacc.2018.04.040. Review.

14.

Prevalence and Risk Factors for Hepatitis B Virus Infection in Roma and Non-Roma People in Slovakia.

Drazilova S, Janicko M, Kristian P, Schreter I, Halanova M, Urbancikova I, Madarasova-Geckova A, Marekova M, Pella D, Jarcuska P; HepaMeta Team.

Int J Environ Res Public Health. 2018 May 22;15(5). pii: E1047. doi: 10.3390/ijerph15051047.

15.

Seroprevalence of Hepatitis E Virus in Roma Settlements: A Comparison with the General Population in Slovakia.

Halánová M, Veseliny E, Kalinová Z, Jarčuška P, Janičko M, Urbančíková I, Pella D, Dražilová S, Babinská I; HepaMeta Team.

Int J Environ Res Public Health. 2018 May 3;15(5). pii: E904. doi: 10.3390/ijerph15050904.

16.

Age-adjusted Mortality Rates of Neoplasms and Circulatory System Diseases and Their Demographic Factors in Slovak Regions during 1996-2013.

Pella D, Fedačko J, Rajnoha R, Gavurová B, Koróny S.

Cent Eur J Public Health. 2017 Dec;25 Suppl 2:S86-S93. doi: 10.21101/cejph.a5056.

17.
18.

Exposure to Toxoplasma gondii in the Roma and Non-Roma Inhabitants of Slovakia: A Cross-Sectional Seroprevalence Study.

Antolová D, Janičko M, Halánová M, Jarčuška P, Gecková AM, Babinská I, Kalinová Z, Pella D, Mareková M, Veseliny E; HepaMeta Team.

Int J Environ Res Public Health. 2018 Feb 27;15(3). pii: E408. doi: 10.3390/ijerph15030408.

19.

A Community-Based Study to Estimate the Seroprevalence of Trichinellosis and Echinococcosis in the Roma and Non-Roma Population of Slovakia.

Antolová D, Halánová M, Janičko M, Jarčuška P, Reiterová K, Jarošová J, Madarasová Gecková A, Pella D, Dražilová S; HepaMeta Team.

Int J Environ Res Public Health. 2018 Feb 2;15(2). pii: E251. doi: 10.3390/ijerph15020251.

20.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center